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Aims To investigate European guideline treatment target achievement in cardiovascular risk factors, medication use, and




In the population-based Tromsø Study 2015–16 (attendance 65%), 904 participants had previous validated MI and/
or stroke. Cross-sectionally, we investigated target achievement for blood pressure (<140/90 mmHg, <130/
80 mmHg if diabetes), LDL cholesterol (<1.8 mmol/L), HbA1c (<7.0% if diabetes), overweight (body mass index
(BMI) <25 kg/m2, waist circumference women <80 cm, men <94 cm), smoking (non-smoking), physical activity (self-
reported >sedentary, accelerometer-measured moderate-to-vigorous >_150 min/week), diet (intake of fruits
>_200 g/day, vegetables >_200 g/day, fish >_200 g/week, saturated fat <10E%, fibre >_30 g/day, alcohol women <_10 g/
day, men <_20 g/day), and medication use (antihypertensives, lipid-lowering drugs, antithrombotics, and antidia-
betics), using regression models. Proportion of target achievement was for blood pressure 55.2%, LDL cholesterol
9.0%, HbA1c 42.5%, BMI 21.1%, waist circumference 15.7%, non-smoking 86.7%, self-reported physical activity
79%, objectively measured physical activity 11.8%, intake of fruit 64.4%, vegetables 40.7%, fish 96.7%, saturated fat
24.3%, fibre 29.9%, and alcohol 78.5%, use of antidiabetics 83.6%, lipid-lowering drugs 81.0%, antihypertensives
75.9%, and antithrombotics 74.6%. Only 0.7% achieved all cardiovascular risk factor targets combined. Largely,
there was little difference between the sexes, and in characteristics, medication use, and lifestyle among target
achievers compared to non-achievers.
...................................................................................................................................................................................................
Conclusion Secondary prevention of cardiovascular disease was suboptimal. A negligible proportion achieved the treatment
target for all risk factors. Improvement in follow-up care and treatment after MI and stroke is needed.
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Favourable lifestyle changes and medication adherence after cardio-
vascular disease (CVD) survival are associated with improved prog-
nosis and lower mortality.1 Despite the known advantages of
secondary prevention and emphasis on the use of guidelines in clinical
practice,2,3 large multicentre and registry studies of patients with
established CVD4–7 have shown that treatment targets are often not
achieved, increasing the risk of recurrent events. Results from the
repeated EUROASPIRE studies,4,5 the longitudinal CLARIFY study6
and the REACH registry7 have shown suboptimal CVD secondary
prevention guideline implementation across countries worldwide.
These studies recruited hospitalized coronary artery disease
(CAD)4,5 or outpatient CAD6 or CVD7 patients, contained limited
data on lifestyle factors beyond smoking4–7 and physical activity,5 and
no data from Norway.
Norwegian register-based studies show an overall declining trend
in incidence of myocardial infarction (MI)8 and ischaemic stroke.9
However, the risk of recurrent events after both MI10 and stroke11 is
high, despite 80–100% of patients are prescribed medications in ac-
cordance with guideline recommendations at hospital discharge.10–13
Two Norwegian hospital-based follow-up studies of patients after
MI14 and stroke13 showed that CVD risk factor control is far from
optimal, despite high medication adherence.
There is a need to study CVD secondary prevention in the
Norwegian general population, using a holistic approach including
guideline implementation of both CVD risk factors, lifestyle factors,
and medication use, and to identify characteristics associated with
target achievement.
The aim of this study was to investigate target achievement in ac-
cordance to the concurrent European Guidelines on CVD preven-
tion in clinical practice2,3 for secondary prevention including CVD
risk factors measurements (blood pressure, lipids, glycated haemo-
globin (HbA1c), body mass index (BMI), and waist circumference),
medication use (antihypertensives, lipid-lowering drugs, antithrom-
botics, and antidiabetics), and a broad range of lifestyle factors (smok-
ing, physical activity, diet, and nutrient intake) after incident MI and
ischaemic stroke, using a population-based sample. We further inves-
tigated differences in women and men, between the diseases, as well




The Tromsø Study is an ongoing population-based study in Tromsø, the
largest municipality of Northern Norway. The 77 000 inhabitants are
served by one of Norway’s six university hospitals. Seven surveys have
been conducted between 1974 and 2016 (Tromsø 1–Tromsø 7), to
which total birth cohorts and representative population samples have
been invited (attendance 65–79%).15 Data collection include question-
naires and interviews, biological sampling, and clinical examinations.
Sample
The present analysis includes participants from Tromsø 7, conducted
from March 2015 to October 2016. All inhabitants 40 years and older
were invited (N = 32 591), of which 65% attended (N = 21 083, aged
40–99 years, 53% women). Prevalence of validated incident MI and is-
chaemic stroke diagnosis any time between first study entry (Tromsø
1–6) and 2015 was 3% (n = 637, 23% women) and 1.5% (n = 308, 35%
women), respectively. Of these, a total of 2/3 occurred <_10 years and
1/3 <_ 5 years before Tromsø 7. Due to diagnosis overlap (n = 41), the
sample for analysis consisted of 904 participants (27% women) with
prevalent MI and/or stroke, of which 14% had diabetes (n = 116). The
study has been approved by the Regional Committee of Medical and
Health Research Ethics (reference REC North 2019/1139), and assessed
by the Norwegian Centre for Research Data (NSD Data Protection
Services) (reference 886376/NSD). All participants gave written
informed consent.
Case validation
Validated CVD endpoints from the Tromsø Study CVD registry were
recorded from first study entry up to 31 December 2014, and were avail-
able for all participants attending Tromsø 7 and one or more of the previ-
ous six surveys. Adjudication of hospitalized and out-of-hospital incident
MI and ischaemic stroke was based on information from medical records
from hospitals, ambulance services, general practitioners, and nursing
homes. Validation of each individual event was based on modified WHO
MONICA (Multinational MONItoring of trends and determinants in car-
diovascular disease)/MORGAM (Monica Risk, Genetics, Archiving, and
Monograph) criteria, described in detail elsewhere.16
Clinical examinations and blood samples
Blood pressure was measured on the right arm, three times with 1-min
intervals after 2 min seated rest by a Dinamap ProCare 300 monitor (GE
Healthcare, Norway), and we used the mean of the two final readings in
the analysis. Non-fasting venous blood samples were collected with stand-
ard methods, and analysed for low-density lipoprotein (LDL) cholesterol
with enzymatic colorimetric methods with commercial kits on a Cobas
8000 c702 (Roche diagnostics, Mannheim, Germany) and HbA1c with
high-performance liquid chromatography methods on a Tosoh G8 (Tosoh
Bioscience, San Francisco, CA, USA) within 48 h at the Department of
Laboratory Medicine, University Hospital of North Norway. BMI (kg/m2)
was calculated by measured height (m) and weight (kg). Waist circumfer-
ence (cm) was measured at the umbilical level by a measuring tape. Trained
personnel performed all measurements.
Questionnaire and accelerometer data
We used questionnaires for data on education (‘What is the highest level of
education you have completed?’: primary, secondary, low or high tertiary),
self-reported health (‘How do you in general consider your own health to be?’:
very bad, bad, neither good or bad, good, and very good), diabetes (‘Do
you have, or have you had, diabetes?’: yes, currently), smoking (‘Do you smoke
daily?’: yes, currently), and self-reported leisure-time physical activity
(Saltin-Grimby Physical Activity Level Scale17: sedentary (reading, watch-
ing TV, or other sedentary activities) or active (walking, cycling, or other
forms of exercise >_4 h/week; recreational sports, heavy gardening >_4 h/
week; hard exercise or competitive sports several times/week)).
Physical activity was also measured objectively in a randomly selected
subsample with an ActiGraph wGT3X-BT accelerometer (ActiGraph,
LLC, Pensacola, FL, USA), worn on the hip for 7 consecutive days and
nights, described in detail elsewhere.18 We included data on minutes in
moderate-to-vigorous physical activity (MVPA) and steps per day, from
participants with valid wear time of four days of at least 10 h.
Dietary data were collected via a previously validated food frequency
questionnaire,19 and food, energy-, and nutrient intakes were calculated
using the food database KBS AE14 and KBS software system at University
of Oslo (KBS, version 7.3.) based on the Norwegian food composition



































































..tables 2014–15,20 described in detail elsewhere.21 We included data on
intake of fruit, vegetables, fish, saturated fat, transfat, fibre, and alcohol, in
grams per day (g/day) or week (g/week), or energy percentage of total
energy intake per day (E%), using only valid data in accordance to
Lundblad et al.21
For use of medication, we combined available data from question-
naires including questions (‘Do you use blood pressure lowering medication?’,
‘Do you use lipid-lowering drugs?’, ‘Do you use insulin?’, ‘Do you use tablet for
diabetes?’) and a self-reported list of brand names of regularly used medi-
cation coded according to the Anatomical Therapeutic Chemical (ATC)
classification system version 201622 (antihypertensives ATC C02, C03,
C07, C08, and C09, lipid-lowering drugs ATC C10, antithrombotics ATC
B01A, and antidiabetics ATC A10, i.e. insulins A10A and oral antidiabetics
A10B). Information about dosage was not available.
Analysis
In accordance with the European Guidelines on CVD prevention in clinic-
al practice version 20122 and 2016,3 we present the prevalence of sec-
ondary prevention target achievement for blood pressure <140/90
(<130/80 if diabetes) mmHg, LDL cholesterol <1.8 mmol/L, HbA1c
<7.0% (i.e. <53 mmol/mol) (if diabetes), normal weight (BMI <25 kg/m2,
waist circumference <80 cm in women and <94 cm in men), non-smoking
(no current daily smoking), active physical activity level (self-reported
>sedentary, accelerometer-measured minutes in MVPA >_150/min per
week in >_10 min bouts), healthy diet (intakes of fruits >_200 g/day, vegeta-
bles >_200 g/day, fish >_200 g/week, saturated fat <10E%, fibre >_30 g/day,
and alcohol <_10 g/day for women and <_20 g/day for men), and use of
antihypertensives, lipid-lowering drugs, antithrombotic drugs, and antidia-
betics (if diabetes).
Results are presented as overall crude percentages, in strata of sex
(age-adjusted) and sex-specific age-groups (40–64 and >_65 years), in the
overall sample (all CVD), and separately for MI and stroke (participants
with both excluded). For stroke, the Norwegian LDL cholesterol target
(<2.0 mmol/L if not diabetes/high risk) was added as a sensitivity analysis.
Logistic regression models with age-adjustment were used to test for evi-
dence of differences between women and men. In separate models, we
added disease (MI or stroke, participants with both excluded) to test for
evidence for differences in target achievement for each disease.
Further, we present differences in characteristics, medication use, and
lifestyle factors (all of the above as well as accelerometer-measured num-
ber of daily steps and intake of transfat) for those achieving and not
achieving the treatment target for each CVD risk factor separately,
including age- and sex-adjusted mean differences or odds ratios with con-
fidence intervals between the groups using linear or logistic regression
models, for continuous variables or proportions, respectively. All analyses
were performed using Stata version 16 (StataCorp. 2019. Stata Statistical
Software: College Station, TX, StataCorp LLC).
Results
Study population
In the total sample of participants with CVD, mean age was 69.6 years
with 30.5% in age-group 40–69 years, 31.0% had tertiary education
and 46.4% reported good or very good health (Table 1). Valid data
from accelerometers and FFQ’s were available for subsamples
(n = 382 and n = 452, respectively).
Cardiovascular disease risk factors,
medication use, and lifestyle factors
Prevalence of target achievement for CVD risk factors varied in the
total sample (Table 2); the lowest proportion was found for LDL
cholesterol (9.0%), followed by waist circumference (15.7%), BMI
(21.1%), and blood pressure (55.2%). Among participants with CVD
and diabetes, 42.5% reached the HbA1c level target, and 83.6% used
antidiabetics. For lifestyle factors, target achievement was lowest for
objectively measured physical activity (11.8%), followed by intake of
saturated fat (24.3%), fibre (29.9%), vegetables (40.7%), fruits
(64.4%), and alcohol (78.5%), self-reported physical activity (79%),
non-smoking (86.7%), and intake of fish (96.7%). Approximately
three out of four used antithrombotics (74.6%) and antihypertensives
(75.9%), and four out of five used lipid-lowering drugs (81.0%). In
total, 54.9% used both antihypertensives, lipid-lowering drugs, and
antithrombotics combined.
Target achievement and medication use were similar in women
and men (Table 2), except for abdominal overweight and vegetable
intake, which were higher in women (P < 0.001 and P = 0.001, re-
spectively). In separate analysis of stroke, the use on antihyperten-
sives was lower in women than in men (Supplementary material
online, Table S2). Target achievement was similar in both diseases
(Table 2, Supplementary material online, Tables S1 and S2), except for
........................................... .............................................
....................................................................................................................................................................................................................
Table 1 Participant characteristics in women and men with cardiovascular disease combined and separately for myo-
cardial infarction and ischaemic stroke











Age at attendance, years 69.6 (10.2) 73.6 (10.4) 69.1 (11.5) 68.8 (9.6) 69.6 (10.2)
Age-group at attendance 40–64 years, % 30.5 (276) 16.3 (24) 36.1 (39) 34.3 (168) 26.0 (52)
Age at diagnosis, years 59.3 (11.3) 64.5 (10.4) 59.6 (13.7) 57.3 (10.5) 61.5 (11.2)
Diabetes, % 14.0 (116) 18.5 (24) 13.5 (12) 14.2 (65) 11.1 (21)
Education tertiary, % 31.0 (264) 13.5 (18) 28.2 (29) 36.3 (169) 30.3 (57)
Self-reported health good/very good, % 46.4 (410) 47.1 (65) 43.0 (46) 47.9 (230) 40.4 (80)
Values are means (standard deviations) and percentages (numbers). The Tromsø Study 2015–16.
CVD, cardiovascular disease (myocardial infarction and/or ischaemic stroke); MI, myocardial infarction.






































use of lipid-lowering drugs and antihypertensives, which was higher
among participants with MI than stroke (P < 0.001 and P = 0.017, re-
spectively), and objectively measured physical activity, which was
higher among participants with stroke than MI (P = 0.005). Using the
Norwegian stroke-specific cut-off for LDL cholesterol changed the
target achievement from 8.2 to 11.6% (Supplementary material on-
line, Table S2).
Target achiever’s characteristics
In total, 0.7% of the participants (n = 6) achieved the treatment tar-
gets for all CVD risk factors combined (Supplementary material on-
line, Table S3). In analysis of single CVD risk factor treatment targets,
those achieving the target were similar to those who did not achieve
the target (Tables 3 and 4), with some exceptions. Those who
achieved the blood pressure target were younger, and a smaller pro-
portion had diabetes, compared to non-achievers (Table 3). Those
who achieved the BMI target were older, had lower vegetable intake,
a higher proportion had tertiary education, and a lower proportion
had diabetes, used antihypertensives, and lipid-lowering drugs, and
were non-smokers, compared to non-achievers (Table 4). Those
who achieved the waist circumference target were more physically
active across both measures, a lower proportion were women, had
diabetes, used antihypertensives, and were non-smokers, compared
to non-achievers (Table 4). Achieving the LDL cholesterol treatment
target was dependent on lipid-lowering drug use (Table 3).
Discussion
The main findings in this study using a general Norwegian population
sample of women and men with validated previous MI and ischaemic
stroke is that a disappointingly low proportion reached the European
treatment targets for secondary prevention. Our results are coher-
ent with previous findings from large international multicentre- and
registry studies.4–7 Of particular worry is that <1% achieved the
treatment target of both blood pressure, LDL cholesterol, and over-
weight combined, which is in line with findings from a nation-wide
....................................... .......................................
....................................................................................................................................................................................................................
Table 2 Secondary prevention target achievement for cardiometabolic risk factors, medication use, and lifestyle, in
women and men with cardiovascular disease (myocardial infarction and/or ischaemic stroke)
Target achievement, % All All women Women All men Men P* P**








Blood pressure 55.2 (453) 52.3 (105) 74.1 (40) 42.2 (65) 56.0 (248) 69.4 (136) 51.0 (212) 0.385 0.647
LDL cholesterol 9.0 (81) 7.0 (17) 9.8 (6) 6.0 (11) 9.7 (64) 10.4 (22) 9.5 (42) 0.212 0.778
HbA1ca 42.5 (48) 44.1 (15) 37.5 (3) 46.2 (12) 41.0 (33) 28.0 (7) 46.4 (26) 0.883 0.614
Body mass index 21.1 (188) 23.2 (58) 31.2 (19) 21.4 (39) 20.2 (130) 15.1 (32) 22.4 (98) 0.338 0.059
Waist circumference 15.7 (140) 8.5 (21) 11.7 (7) 7.7 (14) 18.5 (119) 17.9 (38) 18.5 (81) <0.001 0.235
Antihypertensives 75.9 (686) 73.3 (182) 58.0 (36) 78.9 (146) 77.4 (504) 69.6 (149) 80.1 (355) 0.206 0.017
Lipid-lowering drugs 81.0 (732) 77.5 (190) 77.4 (48) 76.8 (142) 82.4 (542) 85.0 (182) 81.3 (360) 0.102 <0.001
Antithrombotic drugs 74.6 (695) 72.9 (180) 85.5 (53) 68.7 (127) 78.3 (515) 82.7 (177) 76.3 (338) 0.239 0.287
Antidiabeticsa 83.6 (97) 75.8 (25) 87.5 (7) 69.2 (18) 88.0 (72) 96.0 (24) 84.2 (48) 0.107 0.988
Non-smoking 86.7 (770) 86.6 (208) 75.4 (46) 90.0 (162) 88.3 (562) 81.0 (171) 89.7 (391) 0.496 0.244
Physical activity self-report 79.0 (641) 77.3 (156) 87.9 (51) 71.9 (105) 79.6 (485) 82.5 (170) 78.6 (315) 0.490 0.412
Physical activity accelerometerb 11.8 (45) 10.6 (11) 23.8 (5) 7.1 (6) 12.3 (34) 15.0 (9) 11.6 (25) 0.644 0.005
Fruit intakec 64.4 (291) 71.4 (73) 67.6 (25) 72.7 (48) 62.8 (218) 56.3 (63) 65.4 (155) 0.108 0.052
Vegetable intakec 40.7 (184) 54.5 (57) 67.6 (25) 48.5 (32) 35.9 (127) 33.0 (37) 38.0 (90) 0.001 0.190
Fish intakec 96.7 (437) 95.2 (98) 97.3 (36) 93.9 (62) 97.2 (339) 94.6 (106) 98.3 (233) 0.334 0.881
Saturated fat intakec 24.3 (110) 18.8 (21) 18.9 (7) 21.2 (14) 24.4 (89) 32.1 (36) 22.4 (53) 0.228 0.306
Fibre intakec 29.9 (135) 24.9 (27) 29.7 (11) 24.2 (16) 31.0 (108) 34.8 (39) 29.1 (69) 0.303 0.735
Alcohol intakec 78.5 (355) 79.1 (80) 73.0 (27) 80.3 (53) 79.6 (275) 70.5 (79) 82.7 (196) 0.904 0.813
Values are crude (all, age-groups) and age-adjusted (women, men) percentages with numbers of target achievement for blood pressure (<130/80 mmHg if diabetes,
<140/90 mmHg if not diabetes), LDL cholesterol (<1.8 mmol/L), HbA1c (<7.0% if diabetes), body mass index (<25 kg/m2), waist circumference (<80 cm in women, <94 cm in
men), medication use (self-reported use of antihypertensives, lipid-lowering drugs, antithrombotic drugs, and antidiabetics (tablets and/or insulin), smoking (never or former
smoking), physical activity (self-reported leisure time physical activity>sedentary, accelerometer-measured minutes in moderate-to-vigorous physical activity >_150 min/week),
intake of fruit (>_200 g/day), vegetables (>_200 g/day), saturated fat (<10% of the total energy intake), fibre (>_30 g/day), fish (>_200 g/week) and alcohol (<_20 g/day in men,
<_10 g/day in women). The Tromsø Study 2015–16. Numbers vary due to variation in missing values.
aOnly participants with diabetes (n = 116).
bOnly valid accelerometer data included (n = 382).
cOnly valid food frequency questionnaire data included (n = 452).
*P-values (from logistic regression analysis) for difference between women and men (total), adjusted for age.
**P-value (from logistic regression analysis) for difference between disease (myocardial infarction or stroke) [participants with both diseases (n = 41) excluded], adjusted for sex
and age.






































.Norwegian register-based analysis of CVD risk factor control at ad-
mission for acute MI for patients with prior CAD.23
Cardiovascular disease risk factor control
and medication use
In Norway, register-based studies show that one out of four
acute MI hospitalizations are recurrent events,10,23 despite more
than 90% of all patients with MI are prescribed the guideline-rec-
ommended medications at hospital discharge,10,12 and more
than 90% of patients also collect their medications at pharmacies
within 6 months after the event.12 Similarly for stroke, as shown
in a single-hospital follow-up analysis of patients with ischaemic
stroke or TIA in the Norwegian NORSTROKE study, the risk of
recurrent events is high, despite high guideline-recommended
medication use at hospital discharge.11 High medication use at
discharge was also reported in an analysis from the Nor-COAST
multicentre study,13 which included previously hospitalized
patients with stroke from five Norwegian hospitals for repeated
post-event follow-up. In Nor-COAST, despite high medication
adherence over time, CVD risk factor control was suboptimal.13
Similarly, the Norwegian NOR-COR study, which included pre-
viously hospitalized CAD patients from two hospitals for post-
event examination, found CVD risk factors levels to be high
despite more than 90% of patients reporting use of antihyper-
tensives and lipid-lowering drugs.14
Strikingly, we found that only one in ten were below the threshold
for the concurrent LDL cholesterol target, which in the most recent
ESC guidelines for the management of dyslipidaemias presented in
201924 were further reduced to <1.4 mmol/L for very high CVD risk
patients. As the lowering of LDL cholesterol to guideline levels2,3,24
will have to depend on medication use, there is room for improve-
ment by increase in dosage or change of agent, as more than 80% of
the participants in our study reported using lipid-lowering drugs.
The overall medication use in our study was high, but not optimal,
and slightly lower than previously found in patient-studies,4,5,13,14
which could be due to the variation in time since the event in our
study of the general population. By follow-up of two MI-cohorts in
the Tromsø Study during 1994–2008 and 2007–16, respectively, we
have previously found a decrease in medication use but slight overall
improvement over time in target achievement for blood pressure25
.................................................................................... ..................................................................................
....................................................................................................................................................................................................................
Table 3 Characteristics, medication use, and lifestyle factors in study participants with cardiovascular disease (myo-
cardial infarction or/and ischaemic stroke) stratified by target achievement for blood pressure and LDL cholesterol












Age, years 67.2 (10.0) 72.4 (9.5) -5.1 -6.43, -3.74* 68.8 (9.8) 69.7 (10.2) -0.7 -3.06, 1.58
Men, % 76.8 (348) 71.9 (264) 1.2 0.83, 1.61 79.0 (64) 72.1 (590) 1.4 0.81, 2.49
Diabetes, % 8.2 (37) 21.5 (79) 0.3 0.21, 0.49* 18.4 (14) 13.7 (102) 1.5 0.79, 2.70
Education tertiary, % 33.6 (146) 28.8 (100) 1.1 0.79, 1.49 28.6 (22) 31.0 (239) 0.8 0.50, 1.42
Antihypertensives, % 76.2 (345) 78.8 (289) 1.0 0.68, 1.35 75.3 (61) 75.9 (621) 1.0 0.57, 1.66
Lipid-lowering drugs, % 84.1 (381) 80.1 (297) 1.1 0.79, 1.67 100.0 (81) 79.1 (647) 1.0 Perfect prediction
Antithrombotic drugs, % 79.3 (359) 77.9 (286) 0.9 0.63, 1.27 80.3 (65) 76.5 (626) 1.2 0.67, 2.12
Antidiabetics,c % 81.1 (30) 84.8 (67) 0.7 0.24, 2.02 92.9 (13) 82.4 (84) 1.8 0.21, 15.82
Non-smoking, % 84.4 (378) 90.9 (329) 0.7 0.42, 1.03 83.8 (67) 86.9 (698) 0.8 0.42, 1.49
Physically active, % 80.1 (330) 77.3 (255) 1.0 0.70, 1.47 77.0 (57) 79.4 (581) 0.8 0.47, 1.49
MVPA,d min/day 16.2 (18.9) 11.7 (22.7) -0.4 -4.93, 4.22 13.4 (23.8) 14.2 (21.1) -4.3 -11.87, 3.34
Steps,d steps/day 5482 (2694) 5096 (2746) -70 -616.62, 476.16 5171 (1925) 5275 (2732) -119 -1021.47, 781.81
Fruit intake,e g/day 314.5 (267.4) 316.7 (235.0) 5.1 -45.38, 55.50 336.4 (191.6) 319.7 (315.9) 15.7 -80.94, 112.34
Vegetable intake,e g/day 200.7 (131.6) 192.4 (145.3) -1.3 -27.99, 25.42 188.3 (113.9) 198.1 (138.0) -8.1 -50.04, 33.84
Saturated fat intake,e g/day 30.3 (13.7) 29.7 (13.1) 0.7 -1.91, 3.31 31.1 (16.2) 29.9 (13.0) 1.0 -3.08, 5.11
Transfat intake,e g/day 0.7 (0.4) 0.7 (0.4) -0.0 -0.09, 0.07 0.7 (0.5) 0.7 (0.4) 0.0 -0.08, 0.17
Fibre intake,e g/day 26.9 (9.9) 26.3 (9.7) -0.1 -2.08, 1.78 26.1 (10.4) 26.8 (9.8) -0.7 -3.73, 2.41
Fish intake,e g/day 137.2 (75.4) 130.7 (68.5) 8.0 -6.45, 21.55 126.9 (71.1) 135.1 (73.4) -9.2 -31.57, 13.16
Alcohol intake,e g/day 6.1 (12.5) 4.7 (12.7) 0.2 -2.44, 2.89 4.7 (17.9) 5.5 (12.4) 0.5 -3.67, 4.66
Diabetes: self-reported current diabetes, smoking: self-reported never or former smoking, physically active: self-reported leisure time physical activity > sedentary, daily minutes
in MVPA, and steps per day: measured by accelerometer. Numbers vary due to variation in missing values. The Tromsø Study 2015–16.
Diff, difference; CI, confidence interval; g/day, grams per day; min/day, minutes per day; MVPA, moderate-to-vigorous physical activity; OR, odds ratio.
aValues for the met or not met the target achievement groups are crude means (standard deviations), medians (interquartile range), or proportions (numbers).
bValues for differences between treatment target achievers and non-achievers are age- and sex adjusted (when applicable) differences in means from linear (continuous varia-
bles) or odds ratios from logistic (proportions) regression models, with confidence intervals.
cOnly participants with diabetes (n = 116).
dOnly valid accelerometer data included (n = 382).
eOnly valid food frequency questionnaire data included (n = 452).
*P < 0.05 from linear (continuous variables) or logistic (proportions) regression models between treatment target achievers and non-achievers.






































..and lipid levels.26 However, we found little difference in change in
blood pressure and lipids after incident MI when comparing various
time intervals from the event to follow-up.25,26
The use of antihypertensives and lipid-lowering drugs was less
common after stroke compared to MI, in line with findings from the
REACH registry.7 For those with CVD and diabetes combined, the
use of medication was high (as not all patients with diabetes need
pharmacological treatment). However, the achievement of HbA1c
target was similar to that of the general diabetes population.27
Diabetes medication use and target achievement were similar to find-
ings from the Norwegian NOR-COR study,14 and with less than half
of those with CVD and diabetes combined reaching the current gen-
eral target for diabetes control, there is potential for improvement.
Norway has one of the highest per capita gross domestic product
in the world, with a well-performing health care system, low level of
private financing, and cost-sharing ceilings, and the population
health status and healthcare system are similar to that of the other
Nordic countries.28 However, barriers to medication adherence
after both MI and stroke are multifactorial,29–31 therefore, it is im-
portant to identify modifiable predictors for adherence, given the
undisputable role of pharmacological treatment in secondary preven-
tion of CVD.32,33
Lifestyle
Among the lifestyle factors, prevalence of current smoking was lower
than in previous studies of patients with CAD4,5,7,14,23 but higher than
reported among patients with stroke in Nor-COAST,13 and similar
to Tromsø Study participants without prevalent CVD.34 Compared
to previous studies of self-reported physical activity levels among
patients with CAD,5,14 we found a higher proportion engaging in
physical activity. However, there was a large discrepancy in target
achievement defined by self-reported physical activity and objectively
measured MVPA (79% vs. 12%). We have previously found weak cor-
relation between ActiGraph measures and physical activity levels
measured by the Saltin–Grimby questionnaire, but the questionnaire
was found suitable for ranking of physical activity levels when meas-
ured against accelerometer.18 The discrepancy found in this study
could partly be explained by the potential of overestimation of fa-
vourable health habits in self-report data. Further, questionnaires and
accelerometers are not necessarily capturing the same phenomenon
..................................................................................... ................................................................................
....................................................................................................................................................................................................................
Table 4 Characteristics, medication use, and lifestyle factors in study participants with cardiovascular disease
(myocardial infarction or/and ischaemic stroke) stratified by target achievement for general and abdominal overweight












Age, years 71.1 (10.6) 69.2 (10.0) 1.8 0.20, 3.46* 70.1 (10.4) 69.5 (10.1) 1.0 -0.85, 2.83
Men, % 69.2 (130) 73.7 519) 0.8 0.59, 1.20 85.0 (119) 70.7 (530) 2.4 1.48, 3.97*
Diabetes, % 6.9 (12) 15.7 (101) 0.4 0.21, 0.72* 5.2 (7) 15.4 (105) 0.3 0.14, 0.66*
Education tertiary, % 39.0 (69) 29.1 (193) 1.7 1.19, 2.43* 38.4 (51) 29.5 (208) 1.4 0.94, 2.06
Antihypertensives, % 68.6 (129) 78.3 (551) 0.6 0.40, 0.83* 69.3 (97) 77.5 (581) 0.6 0.41, 0.93*
Lipid-lowering drugs, % 76.1 (143) 83.1 (585) 0.7 0.45, 0.99* 78.6 (110) 82.3 (617) 0.8 0.48, 1.18
Antithrombotic drugs, % 78.2 (147) 77.0 (542) 1.2 0.78, 1.72 82.1 (115) 76.3 (572) 1.4 0.90, 2.31
Antidiabetics,c % 75.0 (9) 84.2 (85) 0.7 0.16, 3.22 71.4 (5) 84.8 (89) 0.4 0.06, 2.20
Non-smoking, % 77.3 (143) 89.0 (616) 0.4 0.24, 0.58* 79.6 (109) 87.8 (647) 0.5 0.30, 0.80*
Physically active, % 83.5 (137) 78.6 (504) 1.5 0.92, 2.33 87.2 (109) 78.0 (529) 2.0 1.13, 3.49*
MVPA,d min/day 13.4 (23.7) 14.3 (21.0) 2.9 -2.51, 8.25 17.3 (28.0) 13.7 (21.6) 6.8 0.84, 12.79*
Steps,d steps/day 5619 (2904) 5212 (2595) 454 -178.53, 1088.04 6200 (3016) 5126 (2575) 1050 347.99, 1751.39*
Fruit intake,e g/day 297.4 (192.6) 327.0 (327.4) -29.4 -101.53, 42.83 314.9 (186.2) 322.4 (323.7) -10.9 -90.75, 69.02
Vegetable intake,e g/day 173.9 (120.2) 202.9 (139.1) -31.4 -62.6, -0.10* 185.2 (128.0) 199.6 (137.8) -7.4 -42.10, 27.33
Saturated fat intake,e g/day 27.3 (12.5) 30.7 (13.4) -2.88 -5.93, 0.18 28.6 (14.2) 30.3 (13.2) -2.5 -5.91, 0.85
Transfat intake,e g/day 0.6 (0.4) 0.7 (0.4) -0.1 -0.19, -0.00 0.7 (0.4) 0.7 (0.4) -0.1 -0.16, 0.05
Fibre intake,e g/day 25.5 (7.6) 27.0 (10.2) -1.3 -3.56, 1.03 28.6 (10.0) 26.4 (9.8) 2.2 -0.35, 4.71
Fish intake,e g/day 119.1 (66.1) 137.6 (74.5) -15.8 -32.45, 0.94 126.4 (67.1) 135.3 (74.4) -13.9 -32.4, 4.55
Alcohol intake,e g/day 6.7 (12.5) 5.3 (12.8) 2.0 -1.09, 5.13 6.8 (12.8) 5.4 (12.9) 0.6 -2.84, 4.05
Diabetes: self-reported current diabetes, smoking: self-reported never or former smoking, physically active: self-reported leisure time physical activity > sedentary, daily minutes
in MVPA, and steps per day: measured by accelerometer. Numbers vary due to variation in missing values. The Tromsø Study 2015–16.
Diff, difference; CI, confidence interval; g/day, grams per day; min/day, minutes per day; MVPA, moderate-to-vigorous physical activity; OR, odds ratio.
aValues for the met or not met the target achievement groups are crude means (standard deviations), medians (interquartile range), or proportions (numbers).
bValues for differences between treatment target achievers and non-achievers are age- and sex adjusted (when applicable) differences in means from linear (continuous varia-
bles) or odds ratios from logistic (proportions) regression models, with confidence intervals.
cOnly participants with diabetes (n = 116).
dOnly valid accelerometer data included (n = 382).
eOnly valid food frequency questionnaire data included (n = 452).
*P < 0.05 from linear (continuous variables) or logistic (proportions) regression models between treatment target achievers and non-achievers.































































































(i.e. habitual physical activity level versus a snapshot of the physical ac-
tivity level in a particular time period). A high proportion had intakes
within that recommended for the foods fish, fruits, and alcohol, while
a much lower proportion was within the recommended intakes of
the nutrients saturated fat and fibre.
Smoking, physical activity, and diet are modifiable behaviours with
a huge potential for decreased risk of experiencing recurrent CVD
events. Findings from the international multicentre OASIS trial1 show
that MI patients that continued smoking and did not adhere to diet
and physical activity recommendations had a 3.8-fold increased risk
of a recurrent MI, stroke, or death compared with those who did not
smoke, modified their diet, and engaged in physical exercise. Recent
findings from the NOR-COR study show that the strongest modifi-
able predictors of a recurrent CVD event after MI were smoking,
low physical activity levels, not using lipid-lowering drugs, not taking
part in cardiac rehabilitation programmes, and having diabetes.35 An
intensified focus on lifestyle modification is warranted.36 In a study of
opinions on CVD secondary prevention among European Society of
Cardiology health professionals,37 the respondents agreed that a key
target should be improvement in educational support for patients,
with smoking cessation, physical activity increase, dietary improve-
ment, and motivational counselling for behavioural change as the four
most sought-after priorities.
Sex differences
Several previous studies have found sex differences in secondary pre-
vention, mainly with worse CVD risk factor management in women
compared with men.12,38,39 This was not supported by this study,
where we did not find statistically significant sex differences in treat-
ment target achievement for the main CVD risk factors blood pres-
sure and LDL cholesterol, nor for medication use. The exception
was lower use of antihypertensives in women with stroke compared
with men. A larger proportion of women than men did not meet the
treatment target for abdominal overweight, which is consistent with
findings from the most recent EUROASPIRE study of CAD survivors5
and also with findings from the total population unrelated to disease
status.27
Who achieves cardiovascular disease risk
factor control?
Identification of characteristics associated with CVD risk factor
control can help to develop a more targeted secondary preven-
tion strategy. However, in our study, characteristics differed little
between target achievers and non-achievers. While use of lipid-
lowering drugs was strongly associated with LDL cholesterol con-
trol, use of antihypertensives was not associated with achieve-
ment of blood pressure control. Older age was associated with
normal BMI, while younger age with blood pressure control.
Higher physical activity levels were associated with normal waist
circumference. None of the dietary factors was associated with
CVD risk factor target achievements. The exception was a lower
vegetable intake observed among achievers of the BMI target. This
may partly be explained by differences in total food intake with
body size, as the recommended intakes are in absolute values,2,3
thus not adjusted for total energy intake for the individual. For
blood pressure and overweight, a smaller proportion had diabetes
among target achievers than non-achievers. Education was not
associated with CVD risk factor control, except for BMI. In the
NOR-COR study, no association was found between education
and CVD risk factor control, including BMI.14
Strengths and limitations
Major strengths of this study are the use of a sample from a large
population-based study with reasonably high attendance, and the use
of case validation and validated standardized methods to measure the
risk factors and a large range of lifestyle factors including calculation
of foods and nutrients from extensive food frequency questionnaires,
and objective measurements of physical activity.
The main limitation of this analysis is the cross-sectional design, i.e.
we could not study the change in risk factors after incident CVD
event. Further, only survivors (at the time of the examination) are
included, and we can assume that non-attenders (due to death, dis-
ease, or other causes) had a less favourable risk profile than attend-
ers. In addition, valid case information was limited to participants that
had participated in one or more previous Tromsø Study surveys,
increasing the risk of selection bias. Selection bias is common in
population-based studies, where attenders tend to be healthier than
non-attenders.40 Thus, our results can be biased towards more fa-
vourable risk factors levels than in the total population of people
with CVD. Another limitation is that medication use and lifestyle fac-
tors were mainly self-reported. However, by combining question-
naire questions and ATC-coded medication lists we eliminated the
risk of participants being unaware of the agents in their medications.
Further, self-reporting is prone to social desirability bias, leading to
overestimation of for example medication adherence, or intakes of
healthy foods and physical activity, which could partly explain the dis-
crepancy between medication use and risk factor level, and self-
reported and objectively measured physical activity, respectively.
However, the participants were blinded to this study research ques-
tion, thus potential over-reporting is not believed to be related to
diagnosis. Lastly, the association between risk factors and potential
mediators, such as mental health status, were not examined in this
analysis.
Conclusion
In this analysis of CVD secondary prevention using a Norwegian
population-based sample, we found that treatment target achieve-
ment is suboptimal for CVD risk factors, medication use, and lifestyle,
in both women and men. Only a negligible proportion achieved the
treatment target for both blood pressure, LDL cholesterol, and over-
weight combined. In general, characteristics, medication use, and life-
style differed little between those who achieved the targets
compared to those who did not achieve the targets. There is a need
for intensified improvement in follow-up care and treatment of
patients after MI and stroke.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology online.
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